Exane Derivatives’s Ultragenyx Pharmaceutical RARE Stock Holding History

Exane Derivatives’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11	Closed	-$799	–	889
2022 Q1	$799	Buy	+11	New	+$765	﹤0.01%	822
2021 Q4	–	Sell	-11	Closed	-$992	–	946
2021 Q3	$992	Hold	11	–	–	﹤0.01%	863
2021 Q2	$963	Hold	11	–	–	﹤0.01%	881
2021 Q1	$1.25K	Hold	11	–	–	﹤0.01%	715
2020 Q4	$1.52K	Hold	11	–	–	﹤0.01%	648
2020 Q3	$904	Hold	11	–	–	﹤0.01%	624
2020 Q2	$860	Hold	11	–	–	﹤0.01%	563
2020 Q1	$489	Hold	11	–	–	﹤0.01%	598
2019 Q4	$671	Hold	11	–	–	﹤0.01%	582
2019 Q3	$470	Hold	11	–	–	﹤0.01%	590
2019 Q2	$698	Sell	11 -1,590	-99%	-$101K	﹤0.01%	579
2019 Q1	$111K	Buy	1,601 +783	+96%	+$44.7K	0.02%	287
2018 Q4	$35.6K	Buy	+818	New	+$44.7K	0.01%	395

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Exane Derivatives's RARE Position: Q2 2022 in Review

Exane Derivatives sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 11 shares — an estimated $799 sold.

Exane Derivatives first reported a position in RARE in Q4 2018 and held it in 13 quarters. The position peaked at $111K in Q1 2019. 224 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

Exane Derivatives reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 11 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $799.
Exane Derivatives first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 13 quarters.
Exane Derivatives's Ultragenyx Pharmaceutical position peaked at $111K in Q1 2019.
224 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.